HUE026491T2 - Benztiazol-származékok mint rákellenes szerek - Google Patents

Benztiazol-származékok mint rákellenes szerek Download PDF

Info

Publication number
HUE026491T2
HUE026491T2 HUE09775337A HUE09775337A HUE026491T2 HU E026491 T2 HUE026491 T2 HU E026491T2 HU E09775337 A HUE09775337 A HU E09775337A HU E09775337 A HUE09775337 A HU E09775337A HU E026491 T2 HUE026491 T2 HU E026491T2
Authority
HU
Hungary
Prior art keywords
compound
cyano
group
mmol
ethyl acetate
Prior art date
Application number
HUE09775337A
Other languages
English (en)
Inventor
Masanori Okaniwa
Terufumi Takagi
Masaaki Hirose
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026212&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE026491(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of HUE026491T2 publication Critical patent/HUE026491T2/hu
Publication of HUE026491T4 publication Critical patent/HUE026491T4/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology

Claims (3)

  1. Szabadalmi igénypontok L (Π képktö vegyük! Π) ~a képletben
    R3 Jelentése egy vagy abttfesopoft egy vagy több he lyettesítővel adott esetbeo szohszîitaâh: Ç:^8 eikioatkiesopost vagy egy vagy több hetysttesttóvei adott ekéíboo ssisbsKtitaái heterociklusos csoport; X jeteetése -Ctt vagy ehíRtb, Äel Re jelentése hídrogőmítotti vagy Cj alldiesepöüt;
    Y jekaiése
    vagy képlett; csoport, ahol az A g\ üni adott esetbe« tovább szabsztstöáRbeOzöígyíirá; Zjeiersiésü ( ; ) · NR’CÖ··, C) -NR^CO-W*-. i '}) -N R'4CO«W·0 ·, (4 ) -NR*!CO-W b-O- W·3-. (5) -Nl^CO-W^S-, í6}-NR3CO-W;.RRA; (? ! -NR 'COö·-» P) .rN^CO-CO-, (9) -NR^CüNR·*-, ; 0) -HR^COHRk-Wk, (1!)-NR3COKRk\yb<> vagy ( í 2 )· -CONR ·- kepíbsi csopofk akd R J és Rd otiadegytypek jelentése egymástól fôggetlemR mámgónaíom vttgy a&amp;il* iísopon, W* vs tükiclsgyíkénsl jeJgotése egymástól S5ggetlpr?bl tSty vagy több helyettesítővel adott esetben sznbsattttiib Cj>s aJkikoesopoit, egy vagy több belyedesítóvei adott esetbe;) sz«bs.d:tRíá;í %..yalketüláncsopoíl êg5' vagy több heiyeöeshövd adót: esetibpoS^bsxSíaált C2»ő aikisdéoesofvïrî vagy egy vagy több Mys&amp;esÄ·· vei adott esetben ?z«bs?< ituaU C3 ^ elkiosikileaesopori; bejelentése agy vagy több helyettes abvc: adóit esetben saubszdtuálk 3* Vagy b-tapk gyűrű; és Rá jakoRise ciano csoport -vagys#, % Az L igénypont saemtU vegyidet. ahoi RÁ jelentése (1} egy vagy tóbb helyettesítővel adóit esetben sauhsvtiiuált C;.^ aikilcsopott. <2} egy vagy#feb helyettesítővel acted: esetben szítbszííbtált C3„g; cskioatkiicsoport vagy (3 i egy vagy több helyertexitővei adod esetben sznbsahíMh, 3 ~ iMagű, ffionocíkktsos. nem-aromás heie-foeikkisps csoport; X jelentése -0-, -MM- vagy -NtCI-kV,
    Y jelentése vagy
    Mpfetű csattal, ahol az A gyűrű olym benzolgyörű, ameiyídott esetben aa alább; helyettesítők kitek! I 3 he-jyetieshóvel sxubsztiruálr ( Π C j ,6 alldfesoport és t2) halogénaiom, Z jelentése Hi-NRXÁú-, (2i-NR:;C0-W!··. (3j -HR%OMRÁ- vagy (4}-C0NX képiei# csoport. ahoi mindegyik helyettesítő jeíentése m 1. igénypontban megadott cs R- jelentése (i)eg;y vagy több hely et; es hővel adott esd ben saohszíituálf fenifcsoport vagy (2'í egy vagy több heíyeííesítövei adott esetben »aubsztkuáit, 5- vagy 6-iagú. monoeikaisos, aromás hete-rocikiüsos csoport. 3. A 2. igényponí sttmnll vegyüiet, ahol R* jekslése • I > C : .i, alkilcsoport, hmeíy adott esetben egv 3 - 8-tagó, monociklusos, nem-aromás heterociklusos csoporttá! yatt ljelyertösitve és a?: utóbbi csoport maga is adott esetben ! - 3 €ő aíPcsoportísi helyetíssMí; vagy (2; C,..8 cikkmik ilesoport 4. A 2. igihvvponí szerinti veg\ ük·, ahol % jelentése -0· 5. A 2. igényponí szerinti vegyidéi, ahol Y'jelentése
    kcpJetû csoport, ahol nz A gyűrű olyan benxolgyürtk tins# adott csel hers as alábbi «eiyettesfcAk köaül I - i he-lyeitesitovel sxubszutuái?: (1) C;.y aiki lesöpört és (2) iralögénatoav h. A 2* igénypont ssethhi vagy bist als»! 2 jelentése (1) -NHCO- vagy (2) - MHC(> W5Í>··, ahol W#identése C·.,, alkiiéocsoport, (3) -NHCONH- vagy (4) «CÖNH-képleté csoport. % A % igénypíxh: saorlnh vegyid# ahol ÍV jakintése (1)1 -- 3, a?, alábbiak hösSi tsxigváíasztot! h#ct:essíőveí adott esetben saubs/íkaátt (enncsopor;: (s) halogéoatom, (b) I az ÄÄ k&amp;ktoégvÂSÂt xzobsxíltuáit C}..ô alkilcsopon: il) baiögébatoíh . és (4) ciaoocsoport, <e> I, - 3; ax aiábbt&amp;k fchahl «íogválhsatoít hoiyopssMvfet ado® esétben sxöbxKÖiuÄ aikoxksopon: Ö) haiogésnuosst és (is) eipaocsopöA, |d) I 3 daooesoporlíajadbti esetben kilyeftesüeö; C5,.s cMoaSk&amp;soport -és (e> alkinhcxoport, vagy m I - 3,, -m. alábbiak koxai toagyálas^i: helyettes itével adott esetbe« saubsÄÄ 5- vagy b-taga, tneoodkitosos, aronhts heíeroeskiusos csoport; ifíAbalogéastoso, #) I - 3 halogbnatoísaxíl adott esdhsnItelyeiieskeit Cj,$ alksldsopork |c); Q:5xf> cikloalkiicsopon és (d> fenilesopors &amp; Az L igénypont stmntl vegyül«;, atndy 4 Mtôr4* 't3-iCC7^ïa^-2r|;i;ieïk1.^r!ôpï8Êa?&amp;^M^^^sikî $» betíztía«oh4-illöKÍ)i:thll'3>ii'«lanod-tiet;tetl)beöxatrti4 vagy sója. 9, A:X K vegy&amp;H> am# ben«ilaaol#h)os|fénh]v3:<l-cianovl--mctilsiii)feonaanhd:. *&amp;·..&amp;?· 5- igénypont szeifeíí an«% sz fcsri«m^|^aíö^ii0X5'|-:Í «<%. ïî<As 1. ipnypni SKéjrííítí: vegyülei, amely áfa:
  2. 12. Ás I;. îgêfïypsjîîi: szerinti végète amely sx N-P-«Ííhhw§HP'^PhíM$^^ fenoxij- 1.3 -benal laxol-2- ii ; eíkk^ropánkarboxsmsd vagy sója. 13* -Az 1. igénypont sxermü vegyük:!., IMoxiH^feenztissol-^^^ MvAs !. igénypont vxermtl x-egyület. amely as NÁ7--Cínn^épÁ{íóÁíríi'Siwrmvöi;fpnkiíiv3~íH-karbarnoll}3nu:5c{:ó'eno>:i]-i.3-be«stia2<>í-2-áí}cikk)propánkarboxan'ii<i vagy sója. IS. Az !', IpnypM szerinti vsgyüfeg amely a» N-PAi^o-S-p-ppAiriiMoAömiljpypin'l-iil' karban«)!! ! ammopstoxij-· í .3 -benzliazol-éy il } ctkk^ropsfctkarboxamid. t&amp; Az 1. Ipnypaot tsrnrimi vegyülek aííPno)Íenoxi|~ i .:3iÓ5enzbazöl~2-ö} ciklopropnkpsoxgpä vagy sója.
  3. 17. Ás I. igénypont szerinti vegyülp amely sæ aóetíf|aPöö)féKbxi] · 1,3*benzUa/o1-2-111 űifelopropáolarbox&amp;mtd. IS, öyögysser. amely magába lbgMegys az J* Igónypm szerinti vegyi! lep. P, Az I. igénypont sæeri-s$«sgyilsí«H.·Sj$gë$«èslèeïi vagy kezeíssóbeo valP alkalmazásra.
HUE09775337A 2008-12-02 2009-12-01 Benztiazol-származékok mint rákellenes szerek HUE026491T4 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008307581 2008-12-02
JP2009125256 2009-05-25

Publications (2)

Publication Number Publication Date
HUE026491T2 true HUE026491T2 (hu) 2016-06-28
HUE026491T4 HUE026491T4 (hu) 2017-07-28

Family

ID=42026212

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09775337A HUE026491T4 (hu) 2008-12-02 2009-12-01 Benztiazol-származékok mint rákellenes szerek

Country Status (41)

Country Link
US (2) US8143258B2 (hu)
EP (1) EP2358689B9 (hu)
JP (1) JP5640014B2 (hu)
KR (1) KR101639092B1 (hu)
CN (1) CN102300854B (hu)
AR (1) AR074435A1 (hu)
AU (1) AU2009323274B2 (hu)
BR (1) BRPI0922109A2 (hu)
CA (1) CA2745144C (hu)
CL (1) CL2011001299A1 (hu)
CO (1) CO6400140A2 (hu)
CR (1) CR20110366A (hu)
CY (1) CY1117178T1 (hu)
DK (1) DK2358689T5 (hu)
DO (1) DOP2011000165A (hu)
EA (1) EA019447B1 (hu)
EC (1) ECSP11011165A (hu)
ES (1) ES2557304T3 (hu)
GE (1) GEP20146003B (hu)
HK (1) HK1161236A1 (hu)
HR (1) HRP20151370T1 (hu)
HU (1) HUE026491T4 (hu)
IL (1) IL213184A0 (hu)
JO (1) JO3101B1 (hu)
MA (1) MA32911B1 (hu)
ME (1) ME02331B (hu)
MX (1) MX2011005836A (hu)
MY (1) MY150989A (hu)
NZ (1) NZ593759A (hu)
PE (1) PE20110588A1 (hu)
PL (1) PL2358689T3 (hu)
PT (1) PT2358689E (hu)
RS (1) RS54370B9 (hu)
SG (1) SG171426A1 (hu)
SI (1) SI2358689T1 (hu)
SM (1) SMT201500316B (hu)
TN (1) TN2011000280A1 (hu)
TW (1) TWI436987B (hu)
UY (1) UY32281A (hu)
WO (1) WO2010064722A1 (hu)
ZA (1) ZA201104659B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR066845A1 (es) * 2007-06-05 2009-09-16 Takeda Pharmaceutical Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
EP2181987B9 (en) * 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2013138753A1 (en) * 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
JP2015511632A (ja) * 2012-03-30 2015-04-20 武田薬品工業株式会社 メラノーマの治療におけるraf阻害剤およびmek阻害剤の投与
CN104736202B (zh) 2012-08-22 2021-09-07 康奈尔大学 用于抑制肌成束蛋白的方法
US9670231B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
SG11201600147TA (en) 2013-06-28 2016-02-26 Beigene Ltd Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103382190B (zh) * 2013-07-16 2015-01-14 浙江医药高等专科学校 一类噻唑并环己烷类化合物、其制备方法和用途
CN103435572B (zh) * 2013-07-16 2015-02-04 浙江医药高等专科学校 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
WO2016008048A1 (en) 2014-07-15 2016-01-21 Ontario Institute For Cancer Research Methods and devices for predicting anthracycline treatment efficacy
ES2827024T3 (es) * 2014-12-23 2021-05-19 Dot Therapeutics 1 Inc Combinación de inhibidores de Raf y de taxanos
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
CN109053630B (zh) * 2018-08-22 2022-04-01 中国人民解放军第二军医大学 一种苯并噻唑类衍生物及其用途
US20230148448A9 (en) * 2018-11-07 2023-05-11 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020232445A1 (en) * 2019-05-16 2020-11-19 The Regents Of The University Of California Modulators of pyrimidine nucleotide biosynthetic pathways
AU2021267373A1 (en) 2020-05-06 2022-12-08 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN112094248B (zh) * 2020-09-17 2023-05-12 中国人民解放军海军军医大学 一种取代苯并噻唑类化合物及其用途
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2399026A (en) * 1941-02-06 1946-04-23 Chem Ind Basel Amides of 2-aminoarylenethiazoles
US4096264A (en) * 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1017384B1 (en) 1997-09-26 2004-11-10 Zentaris GmbH Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
PT1140840E (pt) * 1999-01-13 2006-05-31 Bayer Pharmaceuticals Corp Difenilureias substituidas com (.)-carboxiarilo como inibidores de raf-quinase
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション p38キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
NZ513006A (en) * 1999-01-22 2003-10-31 Kirin Brewery Quinoline derivatives and quinazoline derivatives
CA2377771A1 (en) 1999-07-01 2001-01-11 Ajinomoto Co., Inc. Heterocyclic compounds and medical use thereof
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
IL151045A0 (en) 2000-02-07 2003-04-10 Abbott Gmbh & Co Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
WO2001060814A2 (en) 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
ES2218391T3 (es) 2000-03-06 2004-11-16 Smithkline Beecham Plc Derivados de imidazol como inhibidores de raf-cinasa.
MXPA02012596A (es) 2000-06-21 2003-04-10 Hoffmann La Roche Derivados de benzotiazol.
CA2423154A1 (en) 2000-09-21 2002-03-28 David Kenneth Dean Imidazole derivatives as raf kinase inhibitors
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
WO2002044156A2 (en) * 2000-11-29 2002-06-06 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
WO2003022837A1 (en) 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Heterocycle-carboxamide derivatives as raf kinase inhibitors
WO2003022838A1 (en) 2001-09-05 2003-03-20 Smithkline Beecham Plc Pyridine substituted furan derivatives as raf kinase inhibitors
JP2005524668A (ja) 2002-03-01 2005-08-18 スミスクライン ビーチャム コーポレーション ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
SI1499311T1 (sl) 2002-03-29 2010-03-31 Novartis Vaccines & Diagnostic Substituirani benzazoli in njihova uporaba kot inhibitorji Raf kinaze
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US7378233B2 (en) * 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
DE10334663A1 (de) * 2003-07-30 2005-03-10 Merck Patent Gmbh Harnstoffderivate
DE10337942A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
ATE435015T1 (de) 2003-10-16 2009-07-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
US7846959B2 (en) 2004-05-07 2010-12-07 Exelixis, Inc. Raf modulators and methods of use
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006071035A1 (en) 2004-12-31 2006-07-06 Lg Life Sciences, Ltd. Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives
WO2006076376A1 (en) 2005-01-11 2006-07-20 Medicinova, Inc. Topical treatment of solid tumors and ocular neovascularization
EP1841431A4 (en) * 2005-01-26 2009-12-09 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
EP1907387A1 (en) 2005-07-11 2008-04-09 Mitsubishi Tanabe Pharma Corporation An oxime derivative and preparations thereof
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007058482A1 (en) 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Novel inhibitors of protein kinase
ES2654847T3 (es) 2006-04-19 2018-02-15 Novartis Ag Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R
MX2009001349A (es) 2006-08-04 2009-04-17 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso.
US20100029619A1 (en) 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound
WO2008084873A1 (ja) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation オキシム誘導体
JP4328820B2 (ja) 2007-01-10 2009-09-09 田辺三菱製薬株式会社 医薬組成物
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途
WO2008125633A2 (en) 2007-04-13 2008-10-23 Rikshospitalet - Radiumhospitalet Hf Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer
AU2008251381B2 (en) 2007-05-11 2014-10-30 The Johns Hopkins University Biomarkers for melanoma
MX2009012626A (es) 2007-05-23 2009-12-07 Novartis Ag Inhibidores de raf para el tratamiento de cancer de tiroides.
AR066845A1 (es) 2007-06-05 2009-09-16 Takeda Pharmaceutical Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
JP2008307581A (ja) 2007-06-15 2008-12-25 Sanyo Special Steel Co Ltd 管材の洗浄装置
EP2181987B9 (en) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
EP2184285B1 (en) 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2009028655A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP2009125256A (ja) 2007-11-22 2009-06-11 Kandado:Kk 安眠枕
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
US20110081362A1 (en) 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
US20090275546A1 (en) * 2008-04-10 2009-11-05 Istituto Superiore Di Sanita Diagnostic tests and personalized treatment regimes for cancer stem cells
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof

Also Published As

Publication number Publication date
TN2011000280A1 (en) 2012-12-17
KR101639092B1 (ko) 2016-07-12
JP5640014B2 (ja) 2014-12-10
CL2011001299A1 (es) 2012-01-13
US20120214855A1 (en) 2012-08-23
MA32911B1 (fr) 2011-12-01
HUE026491T4 (hu) 2017-07-28
MX2011005836A (es) 2011-06-17
US20100216810A1 (en) 2010-08-26
EP2358689A1 (en) 2011-08-24
WO2010064722A1 (en) 2010-06-10
EA019447B1 (ru) 2014-03-31
MY150989A (en) 2014-03-31
SG171426A1 (en) 2011-07-28
SI2358689T1 (sl) 2016-01-29
TWI436987B (zh) 2014-05-11
ECSP11011165A (es) 2011-07-29
HK1161236A1 (zh) 2012-08-24
CY1117178T1 (el) 2017-04-05
US8143258B2 (en) 2012-03-27
GEP20146003B (en) 2014-01-10
ZA201104659B (en) 2012-08-29
EP2358689B9 (en) 2016-08-03
TW201024272A (en) 2010-07-01
EA201170735A1 (ru) 2011-12-30
ES2557304T3 (es) 2016-01-25
US8497274B2 (en) 2013-07-30
KR20110091039A (ko) 2011-08-10
JP2012510467A (ja) 2012-05-10
JO3101B1 (ar) 2017-09-20
HRP20151370T1 (hr) 2016-01-15
UY32281A (es) 2010-06-30
AR074435A1 (es) 2011-01-19
CN102300854B (zh) 2015-01-07
RS54370B9 (sr) 2020-01-31
BRPI0922109A2 (pt) 2020-09-01
SMT201500316B (it) 2016-01-08
DK2358689T5 (en) 2016-10-10
CR20110366A (es) 2011-08-29
PE20110588A1 (es) 2011-09-08
CA2745144A1 (en) 2010-06-10
DK2358689T3 (en) 2015-12-14
NZ593759A (en) 2012-07-27
AU2009323274B2 (en) 2015-09-17
CN102300854A (zh) 2011-12-28
AU2009323274A1 (en) 2011-07-07
CA2745144C (en) 2017-10-03
CO6400140A2 (es) 2012-03-15
PL2358689T3 (pl) 2016-03-31
EP2358689B1 (en) 2015-09-30
DOP2011000165A (es) 2011-06-30
RS54370B1 (en) 2016-04-28
IL213184A0 (en) 2011-07-31
PT2358689E (pt) 2015-12-30
ME02331B (me) 2016-04-28

Similar Documents

Publication Publication Date Title
DK2358689T5 (en) Benzothiazole as anticancer agents.
US8344135B2 (en) Heterocyclic compound and use thereof
US8324395B2 (en) Heterocyclic compound and use thereof
US8273741B2 (en) Imidazo-pyridazinyl compounds and uses thereof
US8304557B2 (en) Fused heterocycle derivatives and use thereof
US8445509B2 (en) Fused heterocyclic derivatives and use thereof
US8697874B2 (en) Heterocyclic compound and use thereof
WO2009119776A1 (ja) 縮合複素環誘導体およびその用途